Generic Sprycel, Dasatinib

Dasatinib is used for the treatment of blood cancer or also known as chronic myeloid leukemia. Dasatinib is used in patients whose bodies have rejected other medications or if the patient is allergic to other medication. Dasatinib works by blocking the action of the protein that signals cancer cells to multiply, Dasatinib helps to slow or also stop the spread of cancer. 

Dasatib, Invista, Daslemia , Dasanat, Dyronib


Dasatib, Invista, Daslemia , Dasanat, Dyronib, Dsatinib-ML, Dasakast, Spnib

30, 60

Natco, Samarth, Intas, Dr Reddys, Heterri, Metta Lifesciences, Aprazer, Zydus, Aspar Pharma


20 mg, 50 mg, 70 mg



Dasatinib is used for the treatment of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL).
How it Works
Dasatinib is known as an anti cancer medicine, Dasatinib is known as a tyrosine kinase inhibitor. Dasatinib works by blocking the chemical messengers (called tyrosine kinases) which send signals to cells to grow. This in turn stops the cancerous cells growing and increasing in number.
Common Side effects
Some of the potential side effects of Dasatinib can include the symptoms below; Breathing difficulty, Anemia, Fatigue, Infection, Nausea, Rash, Headache, Edema, Reduced blood platelets, Musculoskeletal pain, Vomiting, Abdominal pain, Fever, Bleeding.


What is Dasatinib?

Dasatinib is a powerful cancer-fighting drug that has been lauded for its ability to help people with CML and ALL. This medication slows the progression of signature leukemia cells, so your body won't go around creating new ones. It also breaks down any accumulated genetic material in the blood that may be contributing to your condition. So get yourself on this prescription today!

In rare instances, health care practitioners may refer to the generic medicine name Dasatinib. This generic drug name is from the commercial name Sprycel rather than dasatinib.
Dasatinib is marketed in the United States under the brand name Sprycel, Emcure Pharmaceuticals markets it under the brand name Nextki in India, where it is available for purchase.

Dasatinib is a medicine that targets certain blood cells, called leukemia cells. Leukemia is many different cancers of the blood cell and there are many different subtypes.


What are the uses of Dasatinib?


Dasatinib (DST) is also known as Sprycel. A small molecule inhibitor of the Flt3-ITD and tyrosine kinases c-kit. The most common use of this drug is in the treatment of chronic myelogenous leukemia (CML; it is a type of cancer of the white blood cell) with resistance or intolerance to prior therapy and acute lymphoblastic leukemia (ALL) with resistance.
The dasatinib medicine works in several ways to stop or slow the growth of cancer cells. It blocks a protein that is needed for these cancer cells to grow. The cancer cells can no longer divide and grow into new cancer cells so quickly. In addition, dasatinib may stop some of the cancer cells from growing altogether and they die off (apoptosis). This will reduce the number of cancerous cells in your body over time.


It works by lowering the risk of fever and other side effects. Dasatinib inhibits the action of abnormal proteins that cause cancer cells to grow. As such, it is used to stop the growth of cancer cells
During its action, dasatinib inhibits the action of an abnormal protein that leads to the growth of cancer cells. Thus, its use stops the growth of cancer cells.


It is also used to treat cases of leukemia that do not respond to other drugs including imatinib. 
Dasatinib is also used in the treatment of leukemia CML in children.


This prescription drug can also be used for new diagnosed types of cancer or other purposes. You need to call your doctor or pharmacist for medical advice.


History of Sprycel/Dasatinib


The prescription drug was developed in collaboration with Bristol Myers Squibb and Otsuka Pharmaceutical and is later named after Jagbandhu Das. A Bristol Myers Squibb research fellow who was the program leader for the drug's development.


Approval of Dasatinib as a drug

It was authorized in the US in June 2006 and in Europe in November 2006.

In November 2017, dasatinib was authorized for use in the treatment of children. This treatment with Philadelphia chromosome-positive (Ph+) CML in the chronic phase.
it was included in Phase I and Phase II studies in juvenile patients.

17 individuals from the Phase I study and 29 participants from the Phase II trial were resistant or intolerant to prior therapy with imatinib. 

More than 60% of participants were given 60 mg/m2 of dasatinib tablets once a day. Participants were treated as long as the condition regressed.


Common side effects of Dasatinib


Common Side Effects of Dasatinib:

The following side effects are prevalent (occurring in more than 30% of individuals) however these can be avoided if the product is taken with doctors advise.

  • Low blood count
  • Diarrhea
  • Headache
  • Bleeding
  • Muscle and bone pain
  • Fatigue
  • Fever
  • Rash
  • Nausea
  • Fluid retention
  • Infection

The drug may also cause side effects as a result of the fast killing of cancer cells that it generates. This medicine has been shown to impair bone marrow activity. This activity may result in a decrease in the number of blood cells.


It is a gen 2 tyrosine kinase inhibitor that is used in the treatment of patients. The tr with chronic myelogenous leukemia CML phase. As well as in patients with advanced disease, abdominal pain, who have developed resistance to or intolerance to imatinib. Dasatinib is used in the treatment of patients with imatinib resistance and/or intolerance, chest pain, skin rash, birth control. As well as in the frontline treatment of patients with chronic myeloid leukemia.


It is also used in the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia CML with the Philadelphia chromosome. It induces pulmonary arterial hypertension PAH.


The presence of comorbidities and the presence of BCR-ABL1 kinase domain mutations should always be taken into consideration. When selecting the most appropriate tyrosine kinase inhibitor (eg, dasatinib) for each individual patient. Patients with chronic myeloid leukemia CML should be carefully selected before receiving dasatinib therapy, according to the findings of the current review.



Customers also bought

Popular Products

Similar Product